The role of [18F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors

Cancer Imaging

Volumn 11, Issue 1, 2011, Pages 195-201

  Kaira, Kyoichi ^a,b   Sunaga, Noriaki ^b   Ishizuka, Tamotsu ^b   Shimizu, Kimihiro ^b   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

18F FDG PET; Differential diagnosis; Systemic review; Thymic epithelial tumor

Indexed keywords

ACETIC ACID C 11; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE TRANSPORTER 1; METHIONINE C 11; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG MONITORING; DRUG UPTAKE; EPITHELIUM TUMOR; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; SYSTEMATIC REVIEW; THYMIC CARCINOMA; THYMIC EPITHELIAL TUMOR; THYMOMA; THYMUS CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; WORLD HEALTH ORGANIZATION; ADULT; AGED; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; NEOPLASM; SCINTISCANNING;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYMUS NEOPLASMS;

EID: 82955174861     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2011.0028     Document Type: Review

References (29)

1. Rosai J, Sobin LH. Histological typing of tumours of the thymus. International histological classification of tumours. 2nd ed. New York: Springer; 1999, p. 1-59.
2. Travis WD, Brambillia E, Muller-Hermelink HK, et al. WHO classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.
3. Liu RS, Yoho SH, Huang MH, et al. Use of fluorine-18 fluorodexyglucose positron emission tomography in the detection of thymoma: a preliminary report. Eur J Nucl Med 1995; 22: 1402-7. doi:10.1007/BF01791148.
4. Kubota K, Yamada S, Kondo T, et al. PET imaging of primary mediastinal tumours. Br J Cancer 1996; 73: 882-6. doi:10.1038/bjc.1996.157. (Pubitemid 26110157)
5. 11C-methionine PET and FDG-PET. J Nucl Med 1999; 40: 1595-601.
6. 18F-FDG-PET/CT of thymic epithelial tumors: usefulness of distinguishing and staging tumor subgroups. J Nucl Med 2006; 47: 1628-34.
7. El-Bawab H, Al-Sugair AA, Rafay M, et al. Role of fluorine-18 fluorodexyglucose positron emission tomography in thymic pathology. Eur J Cardiothorac Surg 2007; 31: 731-6. doi:10.1016/j.ejcts.2007.01.024. (Pubitemid 46400514)
8. 18FDG-PET-CT. Ann Nucl Med 2009; 23: 569-77. doi:10.1007/s12149-009-0283-z.
9. 11C-acetate positron emission tomography are useful modalities for diagnosing the histologic type of thymoma. Cancer 2009; 115: 2531-8. doi:10.1002/cncr.24278.
10. Luzzi K, Campione A, Gorla A, et al. Role of fluorine-fluorodeoxyglucose positron emission tomography/computed tomography in preoperative assessment of anterior mediastinal masses. Eur J Cardiothorac Surg 2009; 36: 475-9. doi:10.1016/j.ejcts.2009.03.055.
11. 18F-FDG-PET for the evaluation of thymic epithelial tumors: correlation with the World Health Organization classification in addition to dual-time-point imaging. Eur J Nucl Med Mol Imaging 2009; 36: 1219-25. doi:10.1007/s00259-009-1082-4.
12. 18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010; 28: 3746-53. doi:10.1200/JCO.2009.27.4662.
13. 18FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: preliminary study. Eur J Radiol 2010; Aug 30. [Epub ahead of print].
14. Igai H, Matsuura N, Tarumi S, et al. Usefulness of [F]fluoro-2-deoxy-D- glucose positron emission tomography for predicting the World Health Organization malignancy grade of thymic epithelial tumors. Eur J Cardiothorac Surg 2011; 40: 143-5. doi:10.1016/j.ejcts.2010.09.009.
15. Terzi A, Bertolaccini L, Rizzardi G, et al. Usefulness of 18-FDG-PET/CT in the pre-treatment evaluation of thymic epithelial neoplasms. Lung Cancer 2011; March 23. [Epub ahead of print].
16. 18F-FDG for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer 2008; 61: 350-5. doi:10.1016/j.lungcan.2008.01.003.
17. Berghmans T, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008; 3: 6-12. doi:10.1097/JTO.0b013e31815e6d6b.
18. Ceresoli GL, Chiti A, Zucali PA, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 2006; 24: 4587-93. doi:10.1200/JCO.2006. 06.8999. (Pubitemid 46630956)
19. 18F-FDG uptake on help predict outcome and response after treatment in unresectable thymic epithelial tumors. Ann Nucl Med 2011; 25: 247-53. doi:10.1007/s12149-010-0455-x.
20. Brock CS, Meikle SR, Price P. Dose fluorine-18 fluorodexyglucose metabolic imaging of tumor benefit oncology? Eur J Nucl Med 1997; 24: 691-705. doi:10.1007/s002590050108. (Pubitemid 27299753)
21. Hoffman JM, Waskin HA, Schifter T, et al. The use of FDG-PET in differentiating infectious from malignant central nervous system lesions in patients with AIDS. J Nucl Med 1992; 33: 838.
22. 18F] FDG uptake in non-small cell lung cancer. Eur J Nucl Med 2000; 27: 1778-85. doi:10.1007/s002590000367.
23. 18F-FDG-PET results in lung cancer staging. J Nucl Med 2004; 45: 999-1003.
24. Vleugel MM, Greijer AE, Shvarts et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1 alpha expression in invasive breast cancer. J Clin Pathol 2005; 58: 172-7. doi:10.1136/jcp.2004.019885. (Pubitemid 40193803)
25. Elson DA, Ryan HE, Snow JW, et al. Coordinate up-regulation of hypoxia inducible factor (HIF)-1a and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing 1. Cancer Res 2000; 60: 6189-95.
26. Ryan HE, Polni M, McNulty W, et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 2000; 60: 4010-15. (Pubitemid 30636574)
27. Ishiwata K, Enomoto K, Sasaki T, et al. A feasibility study on L-[1-carbon-11]tyrosine and L-[methyl-carbon-11]methionine to assess liver protein synthesis by PET. J Nucl Med 1996; 37: 279-85.
28. Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44: 213-21.
29. 11C-acetate positron emission tomography imaging for lung adenocarcinoma 1 to 3 cm in size with ground-glass opacity images on computed tomography. Ann Thorac Surg 2005; 80: 2020-5. doi:10.1016/j.athoracsur.2005.06.003.